The Src inhibitor Saracatinib (AZD0530) has been shown to have antitumor activities in cancer cells and is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (NCT04598919). This evidence concerns the gene SRC and cancer.